Maryana Simonova

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 310 citations · Full text

Hematological Malignancy, Once-per-week Selinexor, Medicine +7

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Shambavi Richard, Ajai Chari, Sosana Delimpasi et al. · American Journal of Hematology · 2021 · 29 citations · Full text

Boston Study, Dexamethasone Versus Bortezomib, Pathology +17

Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

Meletios Α. Dimopoulos, Sosana Delimpasi, Maryana Simonova et al. · Journal of Clinical Oncology · 2020 · 25 citations

Cancer Management, Prior Therapies, Pathology +22

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Holger W. Auner, Maria Gavriatopoulou, Sosana Delimpasi et al. · American Journal of Hematology · 2021 · 23 citations · Full text

Boston Study, Pharmacotherapy, Logistic Analysis +17